{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:20:21Z","timestamp":1760347221763,"version":"3.44.0"},"reference-count":9,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T00:00:00Z","timestamp":1755388800000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Case Reports"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, offering durable responses across multiple malignancies. However, these agents can trigger severe immune\u2010related adverse events (irAEs), including drug\u2010induced autoimmune hemolytic anemia (AIHA), which often necessitates treatment discontinuation. While management guidelines for irAEs are well established, the safety and feasibility of ICI rechallenge after resolution of severe hematologic toxicities remain poorly understood. We herein present a case of pembrolizumab\u2010induced warm autoimmune hemolytic anemia that was successfully rechallenged with dostarlimab. In this case report, we describe a 66\u2010year\u2010old female with a history of stage III C2 endometrial cancer who is status post total abdominal hysterectomy, bilateral salpingo\u2010oophorectomy, and omentectomy. She had completed six cycles of adjuvant chemotherapy with paclitaxel and carboplatin. At her 12\u2010month follow\u2010up, elevated CA\u2010125 levels and imaging (CT Abdomen Pelvis with PET\/CT) indicated possible disease recurrence at the vaginal cuff. A subsequent vaginal biopsy confirmed relapse and recurrence of endometrioid adenocarcinoma with squamous differentiation. Given that the tumor is MMR deficient, the patient was started on pembrolizumab along with carboplatin and paclitaxel. However, after the third cycle, she developed IgG\u2010positive warm autoimmune hemolytic anemia, attributed to pembrolizumab, leading to the discontinuation of the drug. She was treated with steroids, resulting in the resolution of her AIHA, and was then re\u2010challenged with dostarlimab and is showing promising results thus far. Our case demonstrates that rechallenge with alternative immune checkpoint inhibitors may be feasible in selected patients who have experienced immune\u2010related adverse events. However, this decision requires careful consideration of multiple factors, including the type and severity of the initial immune\u2010related adverse event, the potential consequences of recurrence, and the availability of alternative treatment options.<\/jats:p>","DOI":"10.1002\/ccr3.70776","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T04:09:35Z","timestamp":1755490175000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Successful Dostarlimab Rechallenge Following Pembrolizumab\u2010Induced Autoimmune Hemolytic Anemia: A Case Report"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8625-3953","authenticated-orcid":false,"given":"Zaid","family":"Khamis","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Northwell Health\/Staten Island University Hospital  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Northwell Health\/Staten Island University Hospital  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Aldalahmeh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Northwell Health\/Staten Island University Hospital  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Barakat","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Northwell Health\/Staten Island University Hospital  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawaraj","family":"Adhikari","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Northwell Health\/Staten Island University Hospital  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghad","family":"Khassawneh","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery Jordan University of Science and Technology  Irbid Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavya","family":"Misri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Northwell Health\/Staten Island University Hospital  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhar","family":"Meekoo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Northwell Health\/Staten Island University Hospital  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,17]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13187"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730320"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003808"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1703481"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0726"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12081031"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2010020\u20100352\u20108"}],"container-title":["Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.70776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:12:18Z","timestamp":1756897938000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccr3.70776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/ccr3.70776"],"URL":"https:\/\/doi.org\/10.1002\/ccr3.70776","archive":["Portico"],"relation":{},"ISSN":["2050-0904","2050-0904"],"issn-type":[{"type":"print","value":"2050-0904"},{"type":"electronic","value":"2050-0904"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2024-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70776"}}